Key result
DOACs and VKAs prolong clotting lag time and alter clot structure vs. control plasma.
Why the study?
Data are limited on how different anticoagulants affect clot structure when clotting is initiated with different triggers.
Do different classes of anticoagulants distinctively modulate fibrin clot structure depending on the clotting agonist used?
Do different classes of anticoagulants distinctively modulate fibrin clot structure depending on the clotting agonist used?
Clot structure assessment by specific triggers like tissue factor can reveal differential phenotypic effects of distinct anticoagulant classes.
Answers are grounded in this paper and cite their sources.
In vitro fibrin changes with anticoagulants should not change practice; leaves open whether agonist-specific effects influence outcomes.
BACKGROUND: Abnormal clot structure has been identified in patients with thrombotic disorders. Anticoagulant therapy offers clear benefits for thrombosis prevention and treatment by reducing blood clot formation and size; nevertheless, there are limited data on the effects of different anticoagulants, where clotting is initiated with different triggers, on clot structure. OBJECTIVES: Our aim was to investigate the effects of vitamin K antagonists and factor Xa inhibitors on clot structure. METHODS: Clots from pooled plasma spiked with rivaroxaban, apixaban, or enoxaparin, as well as plasma from patients on warfarin, were compared to plasma without anticoagulation. The kinetic profile of polymerizing clots was obtained by turbidity, fiber density was determined by confocal microscopy, clot pore size was investigated by permeation, and fiber size was analyzed using scanning electron microscopy. Clotting agonist was either tissue factor or thrombin. RESULTS: Following clotting with tissue factor, all anticoagulated clots had a significantly increased lag time, with the exception of enoxaparin. Rivaroxaban additionally led to significantly less dense and more permeable clots, with thicker fibers. In contrast, turbidity analysis following initiation with thrombin showed few effects of anticoagulation, with only enoxaparin leading to a prolonged lag time. Enoxaparin clots made with thrombin were less dense and more permeable. CONCLUSION: Our results show that anticoagulants modulate clot structure particularly when induced by tissue factor, most likely due to reduction of thrombin generation. We propose that the effects of different anticoagulants could be assessed with a global clot structure measurement such as permeation or turbidity, providing information on clot phenotype.
No takes yet. Share an insight, caveat, or question.
Gauer et al. (2020) studied Thrombosis (n=385). Anticoagulants (Rivaroxaban, Apixaban, Enoxaparin, Warfarin) vs. Unanticoagulated normal pooled plasma was evaluated on Clotting lag time following tissue factor initiation (p=<0.0001). Tissue factor-initiated clotting of plasma containing direct oral anticoagulants or vitamin K antagonists led to significantly increased lag time, decreased fiber density, and increased permeability compared to control plasma.
Synapse has enriched 10 related papers. Consider them for comparative context: